↓ Skip to main content

Dove Medical Press

Article Metrics

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration

Overview of attention for article published in Clinical Ophthalmology, December 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter
3 tweeters
patent
3 patents

Citations

dimensions_citation
38 Dimensions

Readers on

mendeley
74 Mendeley
Title
Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration
Published in
Clinical Ophthalmology, December 2015
DOI 10.2147/opth.s80040
Pubmed ID
Authors

K. Bailey Freund, Chandrakumar Balaratnasingam, Elona Dhrami-Gavazi, Jesse McCann, Quraish Ghadiali

Abstract

Choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) is an important cause of visual morbidity globally. Modern treatment strategies for neovascular AMD achieve regression of CNV by suppressing the activity of key growth factors that mediate angiogenesis. Vascular endothelial growth factor (VEGF) has been the major target of neovascular AMD therapy for almost two decades, and there have been several intravitreally-administered agents that have enabled anatomical restitution and improvement in visual function with continual dosing. Aflibercept (EYLEA(®)), initially named VEGF Trap-eye, is the most recent anti-VEGF agent to be granted US Food and Drug Administration approval for the treatment of neovascular AMD. Biologic advantages of aflibercept include its greater binding affinity for VEGF, a longer intravitreal half-life relative to other anti-VEGF agents, and the capacity to antagonize growth factors other than VEGF. This paper provides an up-to-date summary of the molecular mechanisms mediating CNV. The structural, pharmacodynamic, and pharmacokinetic advantages of aflibercept are also reviewed to rationalize the utility of this agent for treating CNV. Results of landmark clinical investigations, including VIEW 1 and 2 trials, and other important studies are then summarized and used to illustrate the efficacy of aflibercept for managing treatment-naïve CNV, recalcitrant CNV, and CNV due to polypoidal choroidal vasculopathy. Safety profile, patient tolerability, and quality of life measures related to aflibercept are also provided. The evidence provided in this paper suggests aflibercept to be a promising agent that can be used to reduce the treatment burden of neovascular AMD.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
Unknown 73 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 14 19%
Student > Ph. D. Student 12 16%
Student > Master 7 9%
Student > Doctoral Student 6 8%
Researcher 6 8%
Other 12 16%
Unknown 17 23%
Readers by discipline Count As %
Medicine and Dentistry 24 32%
Biochemistry, Genetics and Molecular Biology 6 8%
Pharmacology, Toxicology and Pharmaceutical Science 6 8%
Agricultural and Biological Sciences 2 3%
Immunology and Microbiology 2 3%
Other 9 12%
Unknown 25 34%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 December 2021.
All research outputs
#2,586,073
of 21,322,016 outputs
Outputs from Clinical Ophthalmology
#156
of 2,961 outputs
Outputs of similar age
#45,817
of 356,132 outputs
Outputs of similar age from Clinical Ophthalmology
#7
of 75 outputs
Altmetric has tracked 21,322,016 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,961 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 356,132 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 75 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.